Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02245412
Other study ID # ALXN1007-GIGVHD-201
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 14, 2014
Est. completion date February 27, 2017

Study information

Verified date December 2018
Source Alexion Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this trial were to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of intravenous (IV) ALXN1007 in participants with acute graft-versus-host disease (GVHD) of the lower gastrointestinal (GI) tract.


Description:

This was a Phase 2A open-label, non-randomized study to evaluate the safety, tolerability, PK/PD, and efficacy of ALXN1007 (a C5a inhibitor) in up to 36 participants with newly diagnosed acute GVHD of the lower GI tract. All participants meeting the inclusion and exclusion criteria for the study were to receive ALXN1007 over an 8 week treatment period. Participants in Cohort 1, the first dosing cohort, were to receive 10 milligrams/kilogram (mg/kg) ALXN1007 administered IV once weekly for 8 weeks. Participants in Cohort 2 were to receive 20 mg/kg ALXN1007 IV once weekly for 8 weeks. Participants in Cohort 3 were to receive 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. All doses of ALXN1007 were to be administered as a continuous IV infusion.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date February 27, 2017
Est. primary completion date February 27, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Participants must be males or females age 18 years or older.

- Participants with Stage 1 to 4 (per the Modified Keystone Grading Schema) acute GVHD of the lower GI tract, without signs of chronic GVHD, at the time of diagnosis, which developed in the first 180 days following allogeneic hematopoietic cell transplantation (HCT) using bone marrow, peripheral blood, or cord blood; or after preplanned donor lymphocyte infusion.

- Participants are willing to undergo or must have had an endoscopy of the upper and/or lower GI tract and biopsy to confirm GI GVHD.

- Participants must be receiving systemic corticosteroids.

- Participants with an absolute neutrophil count (ANC) >500/microliter (µL) at Screening.

- Participants and spouse/partner who are of childbearing potential must be using high effective contraception consisting of 2 forms of birth control (at least 1 of which much be barrier method) starting at Screening and continuing through the entire study (for at least 3 months after the last dose of ALXN1007 if study treatment is stopped early or participant withdraws consent).

- Male participants must not donate sperm during the Screening and Treatment periods, and for at least 3 months after the last dose of ALXN1007.

- Stage of acute GVHD of the lower GI tract will be determined using the Modified Keystone Grading Schema.

Exclusion Criteria:

- Participants with a body weight > 140 kg (for Cohorts dosing 20 mg/kg of ALXN1007 and higher only).

- Participants with signs and symptoms of chronic GVHD.

- Participants with an active uncontrolled infection.

- Participants who test positive for Clostridium difficile (C. difficile) at Screening.

- Participants with relapsed/persistent malignancy requiring rapid immune suppression withdrawal.

- Participants who received an unplanned (not part of the original transplant therapy plan) donor lymphocyte infusion.

- Participants who received previous systemic treatment for acute GVHD, except for a maximum of 3 days (72 hours) of 2 mg/kg corticosteroid therapy.

- Participants with unresolved veno-occlusive disease of the liver.

- Participants with creatinine clearance <40 milliliters (mL)/minute at Screening, as calculated by the Cockcroft-Gault formula.

- Participants known to be infected with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.

- Participants known to have an uncontrolled thyroid disorder.

- Participants who are pregnant, breast feeding, or sexually active and unwilling to use effective birth control for the duration of the study.

- Participants who participated in any other investigational drug trial or had exposure to any other investigational agent, device, or procedure <4 weeks prior to Screening and throughout the entire trial, with the exception of investigational drugs administered prophylactically for cytomegalovirus (CMV) post allogeneic HCT.

Study Design


Intervention

Biological:
ALXN1007 10 mg/kg once weekly
ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
ALXN1007 20 mg/kg once weekly
ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
ALXN1007 20 mg/kg twice weekly
ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

Locations

Country Name City State
France Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Centre François Gironde
France CHU de Grenoble - Hôpital Nord Grenoble Isere
France Hôpital Saint-Louis Paris
United States Emory University Hospital Atlanta Georgia
United States Roswell Park Cancer Institute Buffalo New York
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States City of Hope Duarte California
United States Hackensack University Medical Center Hackensack New Jersey
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States University of Minnesota Medicine - Hematology, Oncology and Transplantation Office Minneapolis Minnesota
United States Abramson Cancer Perelman Center for Advanced Medicine, University of Pennsylvania Philadelphia Pennsylvania
United States Washington University in St. Louis Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Alexion Pharmaceuticals

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Acute Graft-Versus-Host Disease (GVHD) Response Rate At Day 28 The number of participants with overall acute GVHD response was determined at Day 28. Acute Overall GVHD is defined as improvement from diagnosis in any organ by at least 1 stage, without progression in any other organ, and with no additional therapy being administered. Acute GVHD staging included skin, liver, and GI assessments, which were to be performed using the Modified Keystone Grading Schema. Deaths were considered nonresponders; otherwise last postbaseline values were carried forward for imputation of missing responses. Modified Keystone Grading Schema: Skin - Stages 0 = No Rash, 1 = Rash <25% body surface area (BSA), 2 = 25% to 50% BSA, 3 = >50% BSA, 4 = bullae, desquamation; Lower GI Tract (stool volume over 24 hours) - Stages 0 = <500 mL, 1 = 500 to 1000 mL, 2 = 1001 to 1500 mL, 3 = >1500 mL, 4 = severe abdominal pain +/- ileus, frank blood, or melena; Liver (bilirubin levels) - Stages 0 = =2 mg/dL, 1 = 2.1 to 3 mg/dL, 2 = 3.1 to 6 mg/dL, 3 = 6.1 to 15 mg/dL, 4 = >15 mg/dL. Day 28
Secondary Pharmacokinetics (PK): Time To Maximum Observed Concentration In Plasma (Tmax) Of IV ALXN1007 The Tmax of ALXN1007 was measured on Treatment Days 1, 28, and 49, from blood samples collected at time points relative to the dosing of ALXN1007. PK assessments were to have been measured from Baseline, Treatment Days 7, 14, 21, 28, 35, 42, 49, 56, and Follow-up Days 86, 180, and Early Termination (ET).
Due to the early termination of the study and the clinical development of the ALXN1007 program, a number of PK analyses were not completed. PK data for the 20 mg/kg ALXN1007 once weekly dosing group and the 20 mg/kg ALXN1007 twice weekly dosing group are not available.
Predose up to 72 hours postdose
Secondary PK: Maximum Observed Concentration In Plasma (Cmax) Of IV ALXN1007 The Cmax of ALXN1007 was measured on Treatment Days 1, 28, and 49, from blood samples collected at time points relative to the dosing of ALXN1007. PK assessments were to have been measured from Baseline, Treatment Days 7, 14, 21, 28, 35, 42, 49, 56, and Follow-up Days 86, 180, and Early Termination (ET).
Due to the early termination of the study and the clinical development of the ALXN1007 program, a number of PK analyses were not completed. PK data for the 20 mg/kg ALXN1007 once weekly dosing group and the 20 mg/kg ALXN1007 twice weekly dosing group are not available.
Predose up to 72 hours postdose
Secondary PK: Area Under The Plasma (Or Serum) Concentration Versus Time Curve (AUC) Of IV ALXN1007 The AUC of ALXN1007 was measured on Treatment Days 1, 28, and 49, from blood samples collected at time points relative to the dosing of ALXN1007. PK assessments were to have been measured from Baseline, Treatment Days 7, 14, 21, 28, 35, 42, 49, 56, and Follow-up Days 86, 180, and Early Termination (ET).
Due to the early termination of the study and the clinical development of the ALXN1007 program, a number of PK analyses were not completed. PK data for the 20 mg/kg ALXN1007 once weekly dosing group and the 20 mg/kg ALXN1007 twice weekly dosing group are not available.
Predose up to 72 hours postdose
See also
  Status Clinical Trial Phase
Recruiting NCT02241018 - MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Phase 2/Phase 3
Completed NCT04539470 - Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase 1
Recruiting NCT02659657 - Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation Phase 2
Completed NCT03497273 - Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects Phase 1
Completed NCT05825833 - Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT
Not yet recruiting NCT06294691 - Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases Phase 3
Not yet recruiting NCT06294678 - Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Phase 3
Recruiting NCT04285424 - FMT for Steroid Resistant Gut Acute GVHD Early Phase 1
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Recruiting NCT02044185 - Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01765634 - Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease Phase 2
Terminated NCT00282503 - Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease Phase 3
Recruiting NCT01521039 - Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Terminated NCT03721965 - Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects Phase 1/Phase 2
Not yet recruiting NCT04971551 - A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Phase 2
Completed NCT02743351 - Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT06394895 - Donor Neutrophil Subsets to Predict the Risk of aGVHD
Terminated NCT05673876 - A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) Phase 1
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease